Literature DB >> 9823662

[Betamethasone versus placebo in Peyronie's disease].

G Cipollone1, M Nicolai, G Mastroprimiano, R Iantorno, D Longeri, R Tenaglia.   

Abstract

The Peyronie's disease or Induratio Penis Plastica, represents one of the most controversial and uncertain points of the modern andrology, since its real etiology is still disputable. Consequently also the non-surgical therapy results as still confused and variable as shown in the considerable number of drugs utilized till now. Our study takes into consideration the injection therapy, by the use of the Betamethasone (corticosteroid), and it tries to explain, how it is possible, the real efficacy of drug versus placebo. The randomized study includes 30 patients. The valuation of the results has been effected in reference to three parameters: disappearance of pain, decrease of plaque volume and consistency of 50%, decrease subjective penile curvature. The data obtained show no significant differences between group A (treated with Betamethasone) and group B (treated with placebo). At twelve months of mean follow-up the pain at erection disappeared in 66.6% of the patients of group A, in 53.3% of the patients of group B. The curvature diminished in 20% of the patients of group A and in 26.6% of the patients of group B. A decrease in plaque volume and consistency was noted in 40% of the patients of group A and in 40% of the patients of group B. The data show that probably the clinical results of the therapy is to refer to a mechanical effect of injected volume and not to the drug action itself.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823662

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  8 in total

1.  [Assessment among German urologists of various conservative treatment modalities for Peyronie's disease. Results of a survey].

Authors:  E W Hauck; T Bschleipfer; S M Haag; V Rohde; W Weidner
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

Review 2.  [Current therapeutic options for Peyronie's disease].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

3.  [Peyronie's disease: diagnostics and therapy].

Authors:  A Hauptmann; T Diemer; W Weidner
Journal:  Urologe A       Date:  2011-05       Impact factor: 0.639

4.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

Review 5.  Pharmacological Management of Peyronie's Disease.

Authors:  Landon W Trost; Serap Gur; Wayne J G Hellstrom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Current and emerging treatment options for Peyronie's disease.

Authors:  Ahmet Gokce; Julie C Wang; Mary K Powers; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2013-01-14

7.  Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study.

Authors:  Alessandro Zucchi; Elisabetta Costantini; Tommaso Cai; Giorgio Cavallini; Giovanni Liguori; Vincenzo Favilla; Gaetano De Grande; Giuseppe D'Achille; Mauro Silvani; Giorgio Franco; Alessandro Palmieri; Paolo Verze; Vincenzo Mirone
Journal:  Sex Med       Date:  2016-03-13       Impact factor: 2.491

Review 8.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.